




RealRate

# PHARMACEUTICAL 2017

## Sonnet BioTherapeutics Holdings Inc. Rank 181 of 292





RealRate

# PHARMACEUTICAL 2017

## Sonnet BioTherapeutics Holdings Inc. Rank 181 of 292



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 142% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 34% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	1,794
Cost of Goods Sold	0
Intangible Assets	18,936
Liabilities, Current	12,111
Liabilities, Non-Current	287
Other Assets	1,243
Other Compr. Net Income	-8,668
Other Expenses	38,719
Other Liabilities	7,383
Other Net Income	-6,595
Other Revenues	41,702
Property and Equipment	11,514
Research and Development	0
Selling, General and Administrative Expense	5,801

Output Variable	Value in 1000 USD
Assets	33,486
Liabilities	19,781
Expenses	44,520
Revenues	41,702
Stockholders Equity	13,705
Net Income	-9,413
Comprehensive Net Income	-13,747
Economic Capital Ratio	37%